Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Total Liabilities (2020 - 2025)

Historic Total Liabilities for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to $5.1 million.

  • Gain Therapeutics' Total Liabilities fell 722.16% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 722.16%. This contributed to the annual value of $4.8 million for FY2024, which is 2067.28% down from last year.
  • According to the latest figures from Q3 2025, Gain Therapeutics' Total Liabilities is $5.1 million, which was down 722.16% from $6.1 million recorded in Q2 2025.
  • Gain Therapeutics' 5-year Total Liabilities high stood at $7.4 million for Q2 2024, and its period low was $3.6 million during Q1 2021.
  • For the 5-year period, Gain Therapeutics' Total Liabilities averaged around $5.5 million, with its median value being $5.7 million (2022).
  • In the last 5 years, Gain Therapeutics' Total Liabilities surged by 6132.69% in 2022 and then plummeted by 2067.28% in 2024.
  • Quarter analysis of 5 years shows Gain Therapeutics' Total Liabilities stood at $4.2 million in 2021, then increased by 25.25% to $5.2 million in 2022, then rose by 15.54% to $6.0 million in 2023, then fell by 20.67% to $4.8 million in 2024, then rose by 5.81% to $5.1 million in 2025.
  • Its last three reported values are $5.1 million in Q3 2025, $6.1 million for Q2 2025, and $5.8 million during Q1 2025.